Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 5, 2011, Pages 858-865

  Chen, Tsung Ming ^a,b   Lin, Chun Che ^a,c   Huang, Pi Teh ^b   Wen, Chen Fan ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Diabetes mellitus; Hepatocellular carcinoma; Metformin; Radiofrequency ablation

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; INSULIN; METFORMIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HAZARD RATIO; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; TUMOR VOLUME;

EID: 79954478103     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06664.x     Document Type: Article

References (39)

1. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
2. Lam VW, Ng KK, Chok KS etal. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J. Am. Coll. Surg. 2008; 207: 20-9.
3. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61-74.
4. Pomfret EA, Washburn K, Wald C etal. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 2009; 16: 262-78.
5. Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant. Rev. 2010; 24: 11-17.
6. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J. Gastrointest. Surg. 2008; 12: 183-91.
7. Tateishi R, Shiina S, Teratani T etal. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
8. Lencioni R, Cioni D, Crocetti L etal. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 961-7.
9. Raut CP, Izzo F, Marra P etal. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann. Surg. Oncol. 2005; 12: 616-28.
10. Takahashi S, Kudo M, Chung H etal. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 (Suppl. 1): 98-103.
11. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999; 10: 313-8.
12. Chow WH, Gridley G, Nyre'n O etal. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J. Natl. Cancer Inst. 1995; 87: 930-1.
13. Hu FB, Manson JE, Liu S etal. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J. Natl. Cancer Inst. 1999; 91: 542-7.
14. Adami HO, Chow WH, Nyre'n O etal. Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl. Cancer Inst. 1996; 88: 1472-7.
15. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am. J. Epidemiol. 2004; 159: 1160-7.
16. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J. Natl. Cancer Inst. 2008; 100: 530-2.
17. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011; 54: 25-31.
18. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-8.
19. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010; 30: 750-8.
20. Huo TI, Wu JC, Lui WY etal. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur. J. Gastroenterol. Hepatol. 2003; 15: 1203-8.
21. Kawamura Y, Ikeda K, Arase Y etal. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J. Gastroenterol. Hepatol. 2008; 23: 1739-46.
22. Ikeda Y, Shimada M, Hasegawa H etal. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998; 27: 1567-71.
23. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point? Diabetologia 2005; 48: 2454-9.
24. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 1): S62-9.
25. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-8.
26. Chen TM, Huang PT, Lin LF, Tung JN. Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single center experience. J. Gastroenterol. Hepatol. 2008; 23 (8 Pt 2): e445-50.
27. Chen TM, Chang TM, Huang PT etal. Management and patient survival in hepatocellular carcinoma: does the physician's level of experience matter? J. Gastroenterol. Hepatol. 2008; 23 (7 Pt 2): e179-88.
28. Villanueva A, Chiang DY, Newell P etal. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-83.
29. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-50.
30. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
31. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5.
32. Jalving M, Gietema JA, Lefrandt JD etal. Metformin: taking away the candy for cancer? Eur. J. Cancer 2010; 46: 2369-80.
33. Landman GW, Kleefstra N, van Hateren KJ etal. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-6.
34. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43.
35. Yang YX. Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 2009; 137: 412-15.
36. Ozasa K. The effect of misclassification on evaluating the effectiveness of influenza vaccines. Vaccine 2008; 26: 6462-5.
37. Chen CL, Yang HI, Yang WS etal. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-21.
38. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-302.
39. Iwadou S, Nouso K, Kuwaki K etal. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int. 2010; 30: 1027-32.